Neoadjuvant Targeted Therapy in Non-Small Cell Lung Cancer and Its Impact on Surgical Outcomes.

Background: The evidence for neoadjuvant targeted therapy in non-small cell lung cancer is limited, with 2 phase 3 trials currently recruiting and no approved indications.

Methods: We describe our experience with the use of neoadjuvant targeted therapy for patients with operable non-small cell lung cancer.

Results: Our focus is on surgical outcomes, which represent an underreported aspect of the patient trajectory. We argue that surgical outcomes are an essential feature of this strategy with significant potential benefits and risks.

Conclusions: Overall, the patient experience can be significantly affected by the use of neoadjuvant targeted therapy and its impact on surgical planning, strategy, and outcomes.